Clinical Trial Update: Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy [Phase 2]

View source ↗

Summary

A phase 2 clinical trial evaluating ixabepilone for recurrent or persistent uterine leiomyosarcoma after prior chemotherapy has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Corpus Leiomyosarcoma
• Uterine Corpus Sarcoma

Drugs mentioned

• Ixabepilone (ixabepilone)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Uterine Corpus Sarcoma, Uterine Corpus Leiomyosarcoma | Phase 2 | Status: COMPLETED | Results posted: 2015-11-03